Defying the slowdown in the semiconductor market, chipmaker Broadcom (NASDAQ: AVGO) reported a sharp increase in third-quarter profit amid strong revenue growth. Earnings topped the Street view while the top-line missed, triggering a stock sell-off on Thursday evening. The company also reaffirmed its full-year 2019 guidance.
In the three-month period, adjusted earnings rose to $5.16 per share from $4.98 per share in the third quarter of last year and exceeded the market’s prediction. Unadjusted profit was $715 million or $1.71 per share, compared to $1.20 billion or $2.71 per share last year.
At $5.52 billion, revenues were higher by 9% from the prior-year quarter but slightly below Wall Street’s consensus forecast. Infrastructure solutions revenue more than doubled to $1.14 billion, while semiconductor solutions revenue dropped 5% to $4.35 billion.
“Our broad portfolio of mission critical semiconductor and infrastructure software solutions, utilized by the world’s largest enterprises, continued to drive sustained revenues and robust cash flow despite a challenging market backdrop,” said CEO Hock Tan.
Meanwhile, the management reaffirmed its full-year 2019 revenue guidance at $22.5 billion, which is expected to generate operating margins of 14.75%. The outlook includes revenues of $17.5 billion from semiconductor solutions and $5 billion from infrastructure software.
During the quarter, the company repurchased 3.5 million shares for $977 million and approved a dividend of $2.65 per share, to be paid on October 1 to stockholders of record on September 23.
Last month, Broadcom acquired the struggling enterprise security business of cybersecurity expert Symantec (SYMC)for about $11 billion. The management expects cost synergies of about $1 billion from the combination a year after the completion of the transaction.
After retreating from the recent peak, Broadcom shares witnessed significant volatility in the last few months. The stock, which gained about 16% since the beginning of the year, dropped 2% during Thursday’s after-hours trading session.
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key